1. Home
  2. IMVT
  3. IMVT News

Latest Immunovant Inc. (IMVT) News on September 15, 2025

Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock?
IMVT

Zacks

3 months ago

Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock?

IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus
IMVT

Zacks

4 months ago

IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus

IMVT

MT Newswires

4 months ago

Immunovant's Fiscal Q4 Net Loss Widens

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025
IMVT

GlobeNewswire

4 months ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025

H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock
IMVT

Insider Monkey

4 months ago

H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock

Is Immunovant, Inc. (IMVT) The Best Stock That Will Bounce Back?
IMVT

Insider Monkey

4 months ago

Is Immunovant, Inc. (IMVT) The Best Stock That Will Bounce Back?

IMVT

MT Newswires

5 months ago

UBS Downgrades Immunovant to Neutral, Price Target is $17

Akeso claims another PD-1/VEGF win; FDA requests more data from Novavax
IMVT

BioPharma Dive

5 months ago

Akeso claims another PD-1/VEGF win; FDA requests more data from Novavax

Immunovant Dives On Its C-Suite Sweep, Narrowed Plans For Leading Drug
IMVT

Investor's Business Daily

5 months ago

Immunovant Dives On Its C-Suite Sweep, Narrowed Plans For Leading Drug

IMVT

MT Newswires

5 months ago

Immunovant Names New CEO, CFO

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
IMVT

GlobeNewswire

5 months ago

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

IMVT

Argus Research

5 months ago

Daily – Vickers Top Buyers & Sellers for 04/14/2025

Is Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires?
IMVT

Insider Monkey

5 months ago

Is Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires?

Immunovant price target raised to $61 from $58 at Stifel
IMVT

TipRanks

6 months ago

Immunovant price target raised to $61 from $58 at Stifel

Immunovant’s batoclimab shows ‘impressive’ efficacy in MG, says H.C. Wainwright
IMVT

TipRanks

6 months ago

Immunovant’s batoclimab shows ‘impressive’ efficacy in MG, says H.C. Wainwright

IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success
IMVT

Zacks

6 months ago

IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success

Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose.
IMVT

Investor's Business Daily

6 months ago

Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose.

Immunovant will not seek approval for MG therapy, despite hitting endpoints
IMVT

Clinical Trials Arena

6 months ago

Immunovant will not seek approval for MG therapy, despite hitting endpoints

Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data
IMVT

Benzinga

6 months ago

Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data

Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled.
IMVT

Investor's Business Daily

6 months ago

Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled.

IMVT

MT Newswires

6 months ago

Immunovant Says Currently Not Planning to Seek Approval of Batoclimab for Myasthenia Gravis; Shares Drop Pre-Bell

Immunovant claims study success for immune disease drug but holds off on submission
IMVT

BioPharma Dive

6 months ago

Immunovant claims study success for immune disease drug but holds off on submission

Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
IMVT

GlobeNewswire

6 months ago

Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
IMVT

GlobeNewswire

6 months ago

Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Incyte (INCY) Up 2.6% Since Last Earnings Report: Can It Continue?
IMVT

Zacks

6 months ago

Incyte (INCY) Up 2.6% Since Last Earnings Report: Can It Continue?

Immunovant, Inc. (IMVT): Among The Stocks With At Least $30 Million In Insider Spending Recently
IMVT

Insider Monkey

6 months ago

Immunovant, Inc. (IMVT): Among The Stocks With At Least $30 Million In Insider Spending Recently

Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity
IMVT

Investor's Business Daily

6 months ago

Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity

IMVT

MT Newswires

6 months ago

Jefferies Initiates Immunovant at Hold With $20 Price Target

Immunovant, Inc. (IMVT): the Most Oversold Pharma Stock to Buy According to Analysts
IMVT

Insider Monkey

7 months ago

Immunovant, Inc. (IMVT): the Most Oversold Pharma Stock to Buy According to Analysts

Immunovant, Inc. (IMVT): Is It The Most Oversold Healthcare Stock to Buy Now?
IMVT

Insider Monkey

7 months ago

Immunovant, Inc. (IMVT): Is It The Most Oversold Healthcare Stock to Buy Now?

IMVT

MT Newswires

7 months ago

Immunovant Insider Sold Shares Worth $322,058, According to a Recent SEC Filing

Immunovant, Inc. (IMVT): Among Stocks Insiders Spent The Most Money On Recently
IMVT

Insider Monkey

7 months ago

Immunovant, Inc. (IMVT): Among Stocks Insiders Spent The Most Money On Recently

Roivant Sciences price target lowered to $12 from $13 at BofA
IMVT

TipRanks

7 months ago

Roivant Sciences price target lowered to $12 from $13 at BofA

Immunovant (IMVT) Loses -15.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
IMVT

Zacks

7 months ago

Immunovant (IMVT) Loses -15.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

IMVT

Thomson Reuters StreetEvents

7 months ago

Q3 2024 Roivant Sciences Ltd Earnings Call

IMVT

MT Newswires

7 months ago

Oppenheimer Adjusts Price Target on Immunovant to $54 From $53, Keeps Outperform Rating

IMVT Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus
IMVT

Zacks

7 months ago

IMVT Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus

IMVT

MT Newswires

7 months ago

Immunovant's Fiscal Q3 Loss Widens

Immunovant Reports Financial Results for the Quarter Ended December 31, 2024
IMVT

GlobeNewswire

7 months ago

Immunovant Reports Financial Results for the Quarter Ended December 31, 2024

Here’s Why Immunovant, Inc. (IMVT) Will Double in 2025
IMVT

Insider Monkey

7 months ago

Here’s Why Immunovant, Inc. (IMVT) Will Double in 2025

Immunovant, Inc. (IMVT): The Biotech Stock with Biggest Upside Potential
IMVT

Insider Monkey

8 months ago

Immunovant, Inc. (IMVT): The Biotech Stock with Biggest Upside Potential

Roivant Sciences buys Immunovant Inc. shares and repurchases its own stock for $336.9 million each
IMVT

GuruFocus.com

8 months ago

Roivant Sciences buys Immunovant Inc. shares and repurchases its own stock for $336.9 million each

Immunovant Announces $450 Million Private Placement
IMVT

GlobeNewswire

8 months ago

Immunovant Announces $450 Million Private Placement

IMVT

MT Newswires

8 months ago

Wolfe Research Downgrades Immunovant to Peer Perform From Outperform

We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth
IMVT

Simply Wall St.

9 months ago

We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth

Immunovant price target lowered to $45 from $47 at Wells Fargo
IMVT

TipRanks

9 months ago

Immunovant price target lowered to $45 from $47 at Wells Fargo

Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in 2024?
IMVT

Insider Monkey

10 months ago

Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in 2024?

IMVT

Thomson Reuters StreetEvents

10 months ago

Q2 2024 Roivant Sciences Ltd Earnings Call

Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
IMVT

Zacks

10 months ago

Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus

IMVT

MT Newswires

10 months ago

Immunovant Fiscal Q2 Net Loss Widens

Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024
IMVT

GlobeNewswire

10 months ago

Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting
IMVT

GlobeNewswire

a year ago

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting

IMVT

MT Newswires

a year ago

Immunovant Insider Sold Shares Worth $261,845, According to a Recent SEC Filing

IMVT

MT Newswires

a year ago

Oppenheimer Adjusts Immunovant Price Target to $53 From $47, Maintains Outperform Rating

Is Immunovant, Inc. (IMVT) the Worst Performing Stock to Buy on the Dip?
IMVT

Insider Monkey

a year ago

Is Immunovant, Inc. (IMVT) the Worst Performing Stock to Buy on the Dip?

Is Roivant Sciences Ltd. (NASDAQ:ROIV) The Best NASDAQ Stock Under $50 To Buy?
IMVT

Insider Monkey

a year ago

Is Roivant Sciences Ltd. (NASDAQ:ROIV) The Best NASDAQ Stock Under $50 To Buy?

IMVT

MT Newswires

a year ago

Citigroup Raises Immunovant's Price Target to $60 From $51, Buy Rating Maintained

What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?
IMVT

Benzinga

a year ago

What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?

Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses
IMVT

Pharmaceutical Technology

a year ago

Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses

IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab
IMVT

Zacks

a year ago

IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab

IMVT

MT Newswires

a year ago

Immunovant's Graves' Disease Drug Shows Improved Efficacy at Higher Doses

Roivant Provides Update on Graves’ Disease Development Program
IMVT

GlobeNewswire

a year ago

Roivant Provides Update on Graves’ Disease Development Program

IMVT

GlobeNewswire

a year ago

Immunovant Provides Update on Graves’ Disease Development Program

Why Is Immunovant (IMVT) Up 13.8% Since Last Earnings Report?
IMVT

Zacks

a year ago

Why Is Immunovant (IMVT) Up 13.8% Since Last Earnings Report?

IMVT

GlobeNewswire

a year ago

Immunovant to Host Graves’ Disease Program Update on September 9, 2024

Are Investors Undervaluing Immunovant, Inc. (NASDAQ:IMVT) By 46%?
IMVT

Simply Wall St.

a year ago

Are Investors Undervaluing Immunovant, Inc. (NASDAQ:IMVT) By 46%?

IMVT

MT Newswires

a year ago

Immunovant Insider Sold Shares Worth $480,052, According to a Recent SEC Filing

IMVT

MT Newswires

a year ago

UBS Trims Price Target on Immunovant to $41 From $42, Maintains Buy Rating

IMVT

Thomson Reuters StreetEvents

a year ago

Q1 2025 Roivant Sciences Ltd Earnings Call

IMVT

GlobeNewswire

a year ago

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024

We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth
IMVT

Simply Wall St.

a year ago

We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth

IMVT

MT Newswires

a year ago

Immunovant Insider Sold Shares Worth $257,888, According to a Recent SEC Filing

IMVT

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 07/11/2024

Dianthus (DNTH) Gains 18% in the Past Month: Here's Why
IMVT

Zacks

a year ago

Dianthus (DNTH) Gains 18% in the Past Month: Here's Why

Immunovant (IMVT) Down 1.6% Since Last Earnings Report: Can It Rebound?
IMVT

Zacks

a year ago

Immunovant (IMVT) Down 1.6% Since Last Earnings Report: Can It Rebound?

IMVT

MT Newswires

a year ago

Oppenheimer Adjusts Immunovant Price Target to $46 From $50, Maintains Outperform Rating

IMVT

Thomson Reuters StreetEvents

a year ago

Q4 2024 Roivant Sciences Ltd Earnings Call

After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay
IMVT

Investor's Business Daily

a year ago

After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay

Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus
IMVT

Zacks

a year ago

Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus

Immunovant changes up plans for closely watched autoimmune drugs
IMVT

BioPharma Dive

a year ago

Immunovant changes up plans for closely watched autoimmune drugs

IMVT

MT Newswires

a year ago

Immunovant Q4 Loss Widens -- Shares Fall After-Hours

Biohaven Tumbles After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
IMVT

Investor's Business Daily

a year ago

Biohaven Tumbles After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump

IMVT

GlobeNewswire

a year ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024

Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
IMVT

Investor's Business Daily

a year ago

Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump

IMVT

MT Newswires

a year ago

Immunovant Insider Sold Shares Worth $479,233, According to a Recent SEC Filing

Wall Street Analysts Think Immunovant (IMVT) Could Surge 68.63%: Read This Before Placing a Bet
IMVT

Zacks

a year ago

Wall Street Analysts Think Immunovant (IMVT) Could Surge 68.63%: Read This Before Placing a Bet

Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
IMVT

Zacks

a year ago

Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand

5 Biotech Stocks Worth Adding to Your Portfolio in 2024
IMVT

Zacks

a year ago

5 Biotech Stocks Worth Adding to Your Portfolio in 2024

Should You Hold Immunovant (IMVT)?
IMVT

Insider Monkey

a year ago

Should You Hold Immunovant (IMVT)?

Here's Why You Should Add Immunovant (IMVT) to Your Portfolio
IMVT

Zacks

a year ago

Here's Why You Should Add Immunovant (IMVT) to Your Portfolio

What Makes Immunovant (IMVT) a New Buy Stock
IMVT

Zacks

a year ago

What Makes Immunovant (IMVT) a New Buy Stock

Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
IMVT

Investor's Business Daily

a year ago

Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results

11 Oversold Biotech Stocks To Buy Right Now
IMVT

Insider Monkey

a year ago

11 Oversold Biotech Stocks To Buy Right Now

10 Stocks George Soros and Insiders Are Crazy About
IMVT

Insider Monkey

2 years ago

10 Stocks George Soros and Insiders Are Crazy About

Why Is Immunovant, Inc. (IMVT) Down 14.7% Since Last Earnings Report?
IMVT

Zacks

2 years ago

Why Is Immunovant, Inc. (IMVT) Down 14.7% Since Last Earnings Report?

IMVT

GlobeNewswire

2 years ago

Immunovant Awarded U.S. Patent for IMVT-1402

Here's Why Immunovant, Inc. (IMVT) is Poised for a Turnaround After Losing -8.02% in 4 Weeks
IMVT

Zacks

2 years ago

Here's Why Immunovant, Inc. (IMVT) is Poised for a Turnaround After Losing -8.02% in 4 Weeks

3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024
IMVT

InvestorPlace

2 years ago

3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024

Immunovant Inc CFO Eva Barnett Sells 2,930 Shares
IMVT

GuruFocus.com

2 years ago

Immunovant Inc CFO Eva Barnett Sells 2,930 Shares

We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth
IMVT

Simply Wall St.

2 years ago

We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth

Share on Social Networks: